Loading organizations...

§ Private Profile · 780 Memorial Drive, Cambridge, MA 02139, US
Jounce Therapeutics, Inc. is a company.
Jounce Therapeutics, Inc. has raised $139.0M across 3 funding rounds.
Key people at Jounce Therapeutics, Inc..
Jounce Therapeutics, Inc. has raised $139.0M in total across 3 funding rounds.
Jounce Therapeutics, Inc. develops clinical-stage immunotherapy, mobilizing the immune system against cancer. It creates product candidates enabling the body's natural defenses to attack tumors. The approach uses a biomarker-driven strategy to identify responsive patient populations, aiming for precise, effective immunotherapeutic interventions.
Founded in 2013, Jounce Therapeutics was established by leading immuno-oncology pioneers. Scientific founders include Richard Murray, Ph.D., Gordon Freeman, Ph.D., and Glenn Dranoff, M.D. Dr. James P. Allison, a Nobel laureate for foundational cancer immunotherapy work, was also a founder, contributing expertise in immune regulation.
Jounce Therapeutics develops immunotherapies for cancer patients, especially those with solid tumors benefiting from novel immune-modulating treatments. Its vision redefines cancer care by delivering effective, durable, immune-mediated therapeutic options. They address unmet oncology needs, striving for transformative patient outcomes through immune system activation.
Jounce Therapeutics, Inc. has raised $139.0M in total across 3 funding rounds.
Jounce Therapeutics, Inc.'s investors include Robert M. Hershberg, Casdin Capital, Cormorant Asset Management, Foresite Capital, Nextech Invest, Omega Funds, Pharmstandard International, Michael Lee, Wellington Management, Cary Pfeffer, Deerfield Management.
Jounce Therapeutics, Inc. has raised $139.0M across 3 funding rounds. Most recently, it raised $36.0M Jounce Therapeutics - Other Equity in July 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 19, 2016 | $36M Venture Round | Robert M. Hershberg | — | Announced |
| Apr 23, 2015 | $56M Series B | — | Casdin Capital, Cormorant Asset Management, Foresite Capital, Nextech Invest, Omega Funds, Pharmstandard International, Michael LEE, Wellington Management | Announced |
| Feb 1, 2013 | $47M Series A | Cary Pfeffer | Deerfield Management | Announced |
Jounce Therapeutics is a clinical‑stage immuno‑oncology company that develops biomarker‑driven therapies to enable the immune system to attack tumors, with programs aimed at patients who are resistant or sensitive to PD‑(L)1 inhibitors[1][4].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Quick take: Jounce is a Third Rock‑launched, clinical‑stage immuno‑oncology company focused on biomarker‑driven, mechanism‑based therapies (notably ICOS and CCR8 programs) that has secured industry partnership(s) and is positioned to influence precision immunotherapy approaches if its clinical programs validate its predictive strategies[2][4].
Key people at Jounce Therapeutics, Inc..